Loading...
XJPX
4582
Market cap23mUSD
Jul 10, Last price  
71.00JPY
1D
2.90%
1Q
-27.55%
Jan 2017
-92.73%
IPO
-94.62%
Name

SymBio Pharmaceuticals Ltd

Chart & Performance

D1W1MN
XJPX:4582 chart
P/E
—
P/S
2.99
EPS
—
Div Yield, %
—
Shrs. gr., 5y
8.79%
Rev. gr., 5y
-15.23%
Revenues
1.31b
-46.69%
1,630,029,0001,191,127,0001,449,972,0001,882,521,0001,955,178,0001,532,054,0001,955,027,0001,933,241,0002,368,112,0003,444,206,0003,835,530,0002,837,753,0002,987,051,0008,252,582,00010,008,338,0005,589,708,0002,452,912,0001,307,648,000
Net income
-4.78b
L+24.59%
20,987,000-217,872,000-642,307,000-2,104,513,000-1,733,320,000-1,605,224,000-1,115,877,000-2,632,095,000-2,313,233,000-3,977,862,000-2,752,533,000-4,376,258,000-4,090,216,0002,032,203,0001,179,238,000-1,962,817,000-3,833,480,000-4,776,194,000
CFO
-4.58b
L+33.92%
154,387,000-211,336,000-753,971,000-2,074,057,000-1,658,588,000-1,677,348,000-1,266,174,000-2,271,686,000-1,960,089,000-3,816,793,000-2,324,547,000-4,350,738,000-4,122,483,000140,042,0001,614,241,000-194,685,000-3,416,518,000-4,575,568,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

SymBio Pharmaceuticals Limited engages in the and development, manufacturing and sales of pharmaceuticals and other related operations in Japan and internationally. It offers SyB V-1901, an antiviral drug for post-transplant infections, blood cancers and solid tumors, and neurodegenerative diseases; SyB L-1701, an RTD liquid formulation; and SyB L-1702, an RI administration under the TREAKISYM name. The company was incorporated in 2005 and is based in Minato, Japan.
URL
https://www.symbiopharma.com/
IPO date
Oct 20, 2011
Employees
122
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT